Clinical trials
Neovascular Age-related Macular Degeneration clinical trials
Below are recruiting neovascular age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 75 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07441642RecruitingPhase 2
Study of FWY003 for geographic atrophy in age-related macular degeneration
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
Huntington Beach, CaliforniaAges 50 years+ - NCT07443826RecruitingPhase 1/Phase 2
Gene therapy for age-related muscle loss and heart health
This trial tests a gene therapy that may help rebuild muscle and improve blood vessel growth in people ages 35 to 75. It's designed for those with stable health conditions and no history of cancer, heart disease, blood clots, or diabetes.
Coxen Hole, Bay IslandsAges 35–75 - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Scottsdale, ArizonaAges 50 years+ - NCT06132035RecruitingPhase 1
CG-P5 eye drops for wet macular degeneration
This study tests a new eye drop (CG-P5) for people with wet age-related macular degeneration. It aims to see if the drops are safe and may help improve vision.
Manchester, ConnecticutAges 50 years+ - NCT07434713Recruiting
Testing early response to Eylea 8mg for wet AMD
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
BernAges 50 years+ - NCT07427160Recruiting
Study on best treatment for bleeding under the retina
This trial looks at whether the type of abnormal blood vessels under the retina affects how well a procedure (pneumatic displacement) works to move a macular hemorrhage (bleeding) out of the central vision area. It may help doctors choose the best approach for patients.
Trento, TrentoAges 50 years+ - NCT07423429Recruiting
Switching to Aflibercept 8 mg for wet AMD
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Nantes, NantesAges 18 years+ - NCT07392255RecruitingPhase 1/Phase 2
Testing CTx001 for geographic atrophy (GA) in AMD
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Carmel, IndianaAges 55 years+ - NCT07367282RecruitingPhase 4
Faricimab for newly diagnosed wet age-related macular degeneration
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
SeongnamAges 50 years+ - NCT07338461Recruiting
High-resolution eye imaging study for healthy and eye disease volunteers
This study uses a special, high-resolution camera to take detailed pictures of the back of the eye. It is testing the camera's ability to see changes in the retina for people who are healthy or have age-related macular degeneration, diabetic retinopathy, or other conditions that affect autofluorescence patterns.
MilanAges 18 years+ - NCT07317934RecruitingPhase 3
Gene therapy for wet age-related macular degeneration
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
Hefei, AnhuiAges 50–80 - NCT04847635Recruiting
Laser test for aging-related macular spots under the retina
This trial studies a mild (“subthreshold”) laser treatment for reticular pseudodrusen (RPD) caused by age-related macular degeneration (AMD). If you qualify, the goal is to see whether the laser helps preserve or improve vision by targeting these specific eye changes.
GenovaAges 55 years+ - NCT07308639Recruiting
Eye disease health data study in Germany
This study looks at health records in Germany to understand how many people have certain eye conditions like age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. It also tests new ways to use this information for research.
LeverkusenAges 18 years+ - NCT06031727RecruitingEarly Phase 1
CRISPR gene therapy for wet age-related macular degeneration
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
Shanghai, Shanghai MunicipalityAges 50–80 - NCT07275840RecruitingPhase 2
Testing IBI302 for wet age-related macular degeneration
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
Shanghai, Shanghai MunicipalityAges 50 years+ - NCT07249216Recruiting
Studying eye fluid to improve treatment for wet age-related macular degeneration
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
SingaporeAges 50 years+ - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Gilbert, ArizonaAges 60 years+ - NCT07215234RecruitingPhase 1/Phase 2
Study of an injection for geographic atrophy in AMD
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Peoria, ArizonaAges 60 years+ - NCT07205887RecruitingPhase 2
Study of EYE103 for wet AMD or macular edema after BRVO
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07185841RecruitingPhase 1/Phase 2
Oral tablets for wet macular degeneration
This trial tests an experimental oral tablet for people with wet age-related macular degeneration. It may offer a new way to treat the condition without frequent eye injections.
BeijingAges 50–85 - NCT07160179RecruitingPhase 1/Phase 2
Study of an eye injection for geographic atrophy
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
Carmel, IndianaAges 50 years+ - NCT07144137Recruiting
Observation study for geographic atrophy progression
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
Mountain View, CaliforniaAges 55 years+ - NCT06351670Recruiting
Monitoring early to moderate age-related macular degeneration with AI
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
ViennaAges 55–99 - NCT06351657Recruiting
Monitoring macular degeneration with AI to detect progression
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
ViennaAges 55–99
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neovascular age-related macular degeneration?
- Yes. Clin2 currently lists 75 recruiting neovascular age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neovascular age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neovascular age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-Related Macular Degeneration
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.